基础医学与临床 ›› 2024, Vol. 44 ›› Issue (5): 719-723.doi: 10.16352/j.issn.1001-6325.2024.05.0719

• 短篇综述 • 上一篇    下一篇

重型再生障碍性贫血治疗的研究进展

傅晨, 李平*   

  1. 山东第二医科大学 临床医学院,山东 潍坊 261053
  • 收稿日期:2023-07-03 修回日期:2023-12-28 出版日期:2024-05-05 发布日期:2024-04-23
  • 通讯作者: *alice022@163.com
  • 基金资助:
    国家自然科学基金(82030005)

Research progress in the treatment of severe aplastic anemia

FU Chen, LI Ping*   

  1. School of Clinical Medicine, Shandong Second Medical University, Weifang 261053, China
  • Received:2023-07-03 Revised:2023-12-28 Online:2024-05-05 Published:2024-04-23
  • Contact: *alice022@163.com

摘要: 重型再生障碍性贫血(SAA)是一种急性且致命性的骨髓衰竭症,其发展速度快且病死率较高,预期结果较差。使用抗淋巴/胸腺细胞球蛋白联合环孢素作为标准疗法来控制再生障碍性贫血(AA)已经成为普遍做法,近年来雄激素、艾曲泊帕等药物的应用使得SAA患者的生存率显著升高。对于那些无法耐受或者再次出现病情恶化的病人来说,可以选择做同种异体造血干细胞移植(HSCT)以获得更好的疗效。HSCT前预处理方法的改进及移植后各种药物的应用,使得移植的成功率升高,移植物抗宿主病的发生率降低,异基因造血干细胞移植已成为临床研究的热门。本研究总结SAA近年来的移植和非移植治疗,分析其疗效及相关优缺点。

关键词: 重型再生障碍性贫血, 免疫抑制治疗, 血小板受体激动剂, 雄激素, 异基因造血干细胞移植

Abstract: Severe aplastic anemia(SAA)is a critically ill disease of the blood system that progresses rapidly, has a high mortality rate, and a very poor prognosis. The application of drugs like androgens and Eltrombopag has significantly increased the survival rate of those with aplastic anemia (AA), compared with horse antithymocyte globulin(H-ATG) and cyclosporine, which was once the standard treatment. Patients who do not respond well to immunotherapy or experience a recurrence of symptoms post-treatment have the option to undergo hematopoietic stem cell transplantation (HSCT). The advancement of pre-treatment techniques for HSCT and the utilization of diverse medications following the transplantation procedure have contributed to reduced incidence of graft versus-host disease (GVHD) and improved transplant success. Allogeneic hematopoietic stem cell transplantation has become a hot topic in clinical research. This study summarizes the transplant and non transplant treatments of SAA in recent years, and analyzes its efficacy and related advantages and disadvantages.

Key words: severe aplastic anemia, immunosuppressive therapy, platelet receptor agonists, androgen, allogeneic hematopoietic stem cell transplantation

中图分类号: